What Next for Aridis Pharmaceuticals Inc (NASDAQ:ARDS) Stock After Decrease in Shorted Shares?

September 16, 2018 - By Darrel Chase

The stock of Aridis Pharmaceuticals Inc (NASDAQ:ARDS) registered a decrease of 92.25% in short interest. ARDS’s total short interest was 2,000 shares in September as published by FINRA. Its down 92.25% from 25,800 shares, reported previously. With 32,000 shares average volume, it will take short sellers 0 days to cover their ARDS’s short positions. The short interest to Aridis Pharmaceuticals Inc’s float is 2.08%.

The stock decreased 5.43% or $0.69 during the last trading session, reaching $12.01. About 13,651 shares traded. Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) has 0.00% since September 16, 2017 and is . It has underperformed by 15.62% the S&P500.

Aridis Pharmaceuticals Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies to treat life-threatening infections. The company has market cap of $94.76 million. The Company’s lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. It currently has negative earnings. The firm is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb that is in Phase IIa trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 to treat infections caused by A. baumannii; AR-201, an anti- respiratory syncytial virus F-protein mAb; and AR-501, an anti-infective therapy to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients.

More notable recent Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) news were published by: Benzinga.com which released: “Benzinga’s Top Upgrades, Downgrades For September 10, 2018” on September 10, 2018, also Benzinga.com with their article: “The Week Ahead: Apple’s Special Event, Mobile World Congress, US Inflation Data On Deck” published on September 10, 2018, 247Wallst.com published: “IPO News This Week: Little Action Last Week, but That Will Change Soon” on August 19, 2018. More interesting news about Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) were released by: Bizjournals.com and their article: “Bay Area’s 10th life science IPO this year raises $26M as No. 11 hopes to fetch $86M” published on August 20, 2018 as well as Seekingalpha.com‘s news article titled: “Stocks To Watch: Apple Event, Chinese Auto IPO To Headline” with publication date: September 08, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.